IP Library › Granted Patent US 12,268,652
Granted Patent B2
US 12,268,652 · App. 18/219,979 · Granted Apr 8, 2025

Method for preventing or limiting progression of myopia

Inventor: Alessandro Filippo (Varmo, IT)
Assignee: Cataltheia Group, Inc.
A61H35/02A61F9/0008G02C7/047G02C7/049G02C2202/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,268,652
App. No.
18/219,979
Granted
Apr 8, 2025
Kind
B2
Abstract

A method for preventing or limiting the progression the myopia includes: providing a soft contact lens. The contact lens includes: a solid polymeric component, which is provided for conferring shape and structure on the contact lens and a liquid component which is distributed in the solid component, and which comprises tyrosine, at a concentration between 1 and 200 mg/l. The method further includes putting the soft contact lens on an eye of a patient so as to apply the compound on the eye.

Claims (12)

1. A method comprising:

providing a soft contact lens comprising:

a solid polymeric component, which is provided for conferring shape and structure on the contact lens; and

a liquid component, provided for preventing or limiting progression of myopia, which is distributed in the solid component, and which comprises tyrosine at a concentration between 1 and 200 mg/L and which further comprises an effective quantity of regulating compounds for regulating rheological properties of the liquid component, the regulating compounds comprising hyaluronic acid or a salt thereof or a polysaccharide, wherein the polysaccharide is galacto xyloglucan, which is extracted from tamarind seeds (TSP); and

putting the soft contact lens on an eye of a patient so as to apply the liquid component on the eye.

2. The method according to claim 1 , further comprising preventing or limiting the progression of myopia via the liquid component acting on the eye.

3. The method according to claim 1 , wherein the liquid component of the contact lens further comprises an effective quantity of an antioxidant compound.

4. The method according to claim 3 , wherein the antioxidant compound comprises vitamin E or vitamin B2 or admixtures thereof.

5. The method according to claim 4 , wherein the vitamin E, when present, has a concentration between 1 and 500 mg/L, and the vitamin B2, when present, has a concentration between 1 and 1000 μg/L.

6. The method according to claim 4 , wherein the vitamin E, when present, has a concentration between 1 and 100 mg/l, and the vitamin B2, when present, has a concentration between 1 and 100 μg/l.

7. The method according to claim 4 , wherein the vitamin E, when present, has a concentration between 2 and 20 mg/l, and the vitamin B2, when present, has a concentration between 2 and 50 μg/l.

8. The method according to claim 1 , wherein the concentration of tyrosine in the liquid component of the contact lens is between more than 10 mg/L and 100 mg/L.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: BF RESEARCH S.R.L.
To: CATALTHEIA GROUP, INC.
Reel/Frame 070390/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2023
From: FILIPPO, ALESSANDRO
To: BF RESEARCH S.R.L.
Reel/Frame 064202/0512 →
Priority Claims (1)
IT 102018000005599 · May 22, 2018 · national
Continuity (2)
Continuation 17057171
Related Publication 20230350231A1 · Nov 2, 2023
References Cited (52)
US 3710796A · Neefe · 1973 [cited by examiner]
US 4466705A · Michelson · 1984 [cited by examiner]
US 4668506A · Bawa · 1987 [cited by applicant]
US 5187207A · Gallas · 1993 [cited by applicant]
US 5284843A · Stone et al. · 1994 [cited by applicant]
US 7132567B2 · Alberte · 2006 [cited by examiner]
US 20060271027A1 · Silvestrini et al. · 2006 [cited by applicant]
US 20120088861A1 · Huang et al. · 2012 [cited by applicant]
US 20140036225A1 · Chehab · 2014 [cited by examiner]
US 20160018671A1 · Waite · 2016 [cited by examiner]
US 20160338947A1 · Leahy · 2016 [cited by examiner]
US 20170326088A1 · Vidyasagar · 2017 [cited by examiner]
US 20170368061A1 · Nguyen et al. · 2017 [cited by applicant]
US 20180094137A1 · Mackay · 2018 [cited by examiner]
CN 103576337B · 2018 [cited by applicant]
CN 105434439B · 2018 [cited by applicant]
EP 0834308A1 · 1998 [cited by applicant]
EP 2693259A1 · 2014 [cited by examiner]
JP S6177822A · 1986 [cited by applicant]
JP H09503752A · 1997 [cited by applicant]
JP 2003055225A · 2003 [cited by applicant]
JP 2004203867A · 2004 [cited by applicant]
JP 2005054437A · 2005 [cited by applicant]
JP 2005084558A · 2005 [cited by applicant]
JP 2005154437A · 2005 [cited by applicant]
JP 2010204597A · 2010 [cited by applicant]
JP 2013190789A · 2013 [cited by applicant]
JP 2014032404A · 2014 [cited by applicant]
JP 2015509205A · 2015 [cited by applicant]
JP 2018532835A · 2018 [cited by applicant]
WO 8901639A1 · 1989 [cited by applicant]
WO 2010039939A1 · 2010 [cited by applicant]
WO 2016187426A1 · 2016 [cited by applicant]
WO 2017055536A1 · 2017 [cited by applicant]
WO 2017140846A1 · 2017 [cited by applicant]
WO 2017177262A1 · 2017 [cited by applicant]
International Preliminary Report on Patentability issued Dec. 3, 2020, by the International Bureau of WIPO for 3CT/IB2019/054016. [cited by applicant]
Morgan IG et al.; The epidemics of myopia: aetiology and prevention. Prog Retin Eye Res 2018; 62:134-49; (2017). [cited by applicant]
Yanxian C et al.; Best practice in myopia control: insights and innovations for myopia prevention and control—a round table discussion. Br J Ophthalmol 2024; 108(7) 913-4; (May 10, 2024). [cited by applicant]
Feldkaemper M and Schaeffel F.; An updated view on the role of dopamine in myopia Experimental Eye Research 2013; 114:106-19; (Feb. 19, 2013). [cited by applicant]
Thomson K et al.; Effectiveness and safety of topical levodopa in a chick model of myopia. Scientific Reports 2019; 9:18345. doi.org/10.1038/s41598-019-54789-5; (Dec. 4, 2019). [cited by applicant]
Torii H et al.; Violet light exposure can be a preventive strategy against myopia progression. EBioMedicine 2017; 15:210-9; (Dec. 16, 2016). [cited by applicant]
DelMonte DW and Kim T.; Anatomy and physiology of the cornea. J Cataract Refract Surg 2011; 37:588-98; (Oct. 29, 2010). [cited by applicant]
Bodor N, Buchwald P.; Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J 2005;7(4) Article 79:E820; (Dec. 7, 2005). [cited by applicant]
Santana CP et al.; Corneal Permeability and Uptake of Twenty-Five Drugs: Species Comparison and Quantitative Structure—Permeability Relationships. Pharmaceutics 2023, 15, 1646, at 2; (Jun. 2, 2023). [cited by applicant]
Weng Y et al.; Nanotechnology-based strategies for treatment of ocular disease, Acta Pharmaceutica Sinica 2017; B281, at 281; (Jul. 6, 2016). [cited by applicant]
Vinciguerra P et al.; Use of amino acids in refractive surgery. Journal of Refractive Surgery 2002; 18:S374-377; (Dec. 14, 2001). [cited by applicant]
Marx S et al.; Objective analysis of pre-lens tear film stability of daily disposable contact lenses using ring mire projection. Clinical Optometry 2020; 12:203-11; (Dec. 2020). [cited by applicant]
Wilson SL et al.; Control of scar tissue formation in the cornea: strategies in clinical and corneal tissue engineering. J Funct Biomater 2012; 642:648; (Sep. 18, 2012). [cited by applicant]
Rusciano D et al.; Free amino acids: an innovative treatment for ocular surface disease. European Journal of Pharmacology 2016; 787: 9-19; (Apr. 14, 2016). [cited by applicant]
Hirshfield, GS; Why can't I use my skin ointment on my eyes?, American Academy of Ophthalmology, available at https://www.aao.org/eye-health/ask-ophthalmologist-q/why-can-t-i-use-my-skin-ointment-on-my-eyes#:˜:text=Answ… [cited by applicant]
Zhou X et al.; Dopamine signaling and myopia development: what are the key challenges. Progress in Retinal and Eye Research 2017; 61:60-71; (Jun. 7, 2017). [cited by applicant]